OCT and RCM-assisted sampling might also play a pivotal role in monitoring therapeutic responses at a cellular level by tracking the tumor mutational burden or evaluating the expression of immune biomarkers such as PD-L1 in cutaneous malignancies [111]. Here, CD274 is linked to neoplasm.